Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15481059 | 0.78 | PSMD14 (0.33) | — | |
| SCHEMBL22222003 | 0.70 | ALDH1A1 (0.33) | — | |
| SCHEMBL21516635 | 0.69 | AGBL2 (0.34) | — | |
| SCHEMBL26061532 | 0.68 | TRPM8 (0.34) | — | |
| SCHEMBL19919593 | 0.64 | ESR1 (0.37) | — | |
| SCHEMBL23025662 | 0.64 | — | — | |
| SCHEMBL20288203 | 0.64 | NOS3 (0.30) | — | |
| SCHEMBL23231057 | 0.63 | ESR1 (0.31) | — | |
| SCHEMBL21139917 | 0.63 | CYP3A4 (0.37) | — | |
| SCHEMBL24868587 | 0.62 | RXRA (0.34) | RXRAGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210052612-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2021-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210052612-A1 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS | C5AR2, C5AR1, C3AR1 | RXRA 3114/4885GRIN1 2026/4885GRIN2B 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.